Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 221

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 221
---
 de Vries, M.D.
has served as a non-executive member of our Board of Directors since October 2004 (including his service to our predecessor entity). Since
November 2008, Dr. de Vries has served as of the Chief Executive Officer of Pharming Group NV (Euronext: PHARM). Prior to that, Dr. de
Vries served as Chief Executive Officer of 4-Antibody and Morphochem AG. Prior to this he worked at Novartis Pharma, Novartis Ophthalmics
and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr. de Vries holds an M.D. degree
from the University of Amsterdam and a Masters of Business Administration in General Management from Ashridge Management College (United
Kingdom).

| 109 |

Ann Merchant has served
as a non-executive member of our Board of Directors since December 2023. Ms. Merchant has served as Vice President for MorphoSys AG (NASDAQ:
MOR), a commercial stage biopharmaceutical company headquartered in Munich, Germany, since 2018, and as Head of Global Supply Chain and
External Operations since January 2019. From September 2011 to August 2018, Ms. Merchant served as the President for Schreiner Medipharm,
a business unit of the Schreimer Group Gmbh & Co. KG. Between 1994 and 2011, Ms. Merchant held various roles at Amgen Inc. (NASDAQ:
AMGN), including Vice President, Head of International Supply Chain and Site Head between 2007 and 2011. Ms. Merchant currently serves
on the board of directors of Alvotech S.A. (NASDAQ: ALVO), a biosimilar company. Ms. Merchant holds an MBA from the Henley Business
School and a Bachelor of Science in Languages from Georgetown University.

Compensation of Non-Executive Directors

Our non-executive directors
receive a fee for their services as a director, which is approved by our Board of Directors, giving due consideration to the time commitment
and responsibilities of their roles and of current market rates for comparable organizations and appointments. Non-executive directors
are reimbursed for travelling and other incidental expenses incurred on our business in accordance with our expenses policy.

The following table summarizes
the compensation paid to our non-employee directors during 2024.

| Name            |     | Fees Earned  
 or           
 Paid in Cash